Cubist Systematic Strategies LLC trimmed its holdings in Eli Lilly and Company (NYSE:LLY) by 78.7% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 6,408 shares of the company’s stock after selling 23,738 shares during the quarter. Cubist Systematic Strategies LLC’s holdings in Eli Lilly and were worth $527,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Monetary Management Group Inc. raised its stake in shares of Eli Lilly and by 4.0% in the second quarter. Monetary Management Group Inc. now owns 17,535 shares of the company’s stock valued at $1,443,000 after purchasing an additional 675 shares in the last quarter. Cornerstone Capital Management Holdings LLC. raised its stake in shares of Eli Lilly and by 57.7% in the second quarter. Cornerstone Capital Management Holdings LLC. now owns 295,238 shares of the company’s stock valued at $24,296,000 after purchasing an additional 108,079 shares in the last quarter. Peapack Gladstone Financial Corp raised its stake in shares of Eli Lilly and by 3.9% in the second quarter. Peapack Gladstone Financial Corp now owns 61,110 shares of the company’s stock valued at $5,029,000 after purchasing an additional 2,292 shares in the last quarter. Colonial Trust Advisors raised its stake in shares of Eli Lilly and by 50.2% in the second quarter. Colonial Trust Advisors now owns 49,407 shares of the company’s stock valued at $4,066,000 after purchasing an additional 16,504 shares in the last quarter. Finally, Janus Henderson Group PLC raised its stake in shares of Eli Lilly and by 7,093.5% in the second quarter. Janus Henderson Group PLC now owns 9,353,275 shares of the company’s stock valued at $769,774,000 after purchasing an additional 9,223,251 shares in the last quarter. 76.61% of the stock is owned by institutional investors.

A number of research analysts recently commented on LLY shares. BMO Capital Markets restated a “sell” rating and issued a $71.00 target price on shares of Eli Lilly and in a research note on Thursday, September 28th. Morgan Stanley set a $86.00 target price on Eli Lilly and and gave the company a “hold” rating in a research note on Friday, October 6th. Piper Jaffray Companies restated a “buy” rating and issued a $105.00 target price on shares of Eli Lilly and in a research note on Friday, October 13th. Berenberg Bank restated a “buy” rating and issued a $98.00 target price on shares of Eli Lilly and in a research note on Friday, August 4th. Finally, Jefferies Group LLC restated a “buy” rating and issued a $89.00 target price (down from $94.00) on shares of Eli Lilly and in a research note on Thursday, August 24th. Three research analysts have rated the stock with a sell rating, eight have given a hold rating and ten have assigned a buy rating to the stock. The stock presently has an average rating of “Hold” and an average target price of $89.97.

ILLEGAL ACTIVITY NOTICE: “Cubist Systematic Strategies LLC Trims Stake in Eli Lilly and Company (LLY)” was originally reported by Watch List News and is the sole property of of Watch List News. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this piece can be read at https://www.watchlistnews.com/cubist-systematic-strategies-llc-trims-stake-in-eli-lilly-and-company-lly/1723844.html.

In other news, SVP Alfonso G. Zulueta sold 2,003 shares of the firm’s stock in a transaction on Friday, November 10th. The stock was sold at an average price of $83.67, for a total value of $167,591.01. Following the completion of the sale, the senior vice president now directly owns 43,580 shares in the company, valued at $3,646,338.60. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, major shareholder Lilly Endowment Inc sold 180,000 shares of the firm’s stock in a transaction on Thursday, August 31st. The shares were sold at an average price of $81.06, for a total value of $14,590,800.00. Following the completion of the sale, the insider now owns 123,865,804 shares of the company’s stock, valued at $10,040,562,072.24. The disclosure for this sale can be found here. Insiders have sold 772,003 shares of company stock valued at $64,837,441 over the last quarter. Corporate insiders own 0.20% of the company’s stock.

Eli Lilly and Company (NYSE LLY) opened at $83.68 on Friday. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.03 and a current ratio of 1.38. Eli Lilly and Company has a 12 month low of $64.18 and a 12 month high of $89.09. The stock has a market capitalization of $92,139.64, a price-to-earnings ratio of 20.46, a price-to-earnings-growth ratio of 1.85 and a beta of 0.34.

Eli Lilly and (NYSE:LLY) last released its quarterly earnings data on Tuesday, October 24th. The company reported $1.05 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.03 by $0.02. Eli Lilly and had a return on equity of 30.27% and a net margin of 9.90%. The firm had revenue of $5.66 billion during the quarter, compared to analyst estimates of $5.52 billion. During the same period in the prior year, the company posted $0.88 earnings per share. The business’s revenue for the quarter was up 9.0% compared to the same quarter last year. equities analysts anticipate that Eli Lilly and Company will post 4.21 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, December 8th. Shareholders of record on Wednesday, November 15th will be paid a dividend of $0.52 per share. The ex-dividend date of this dividend is Tuesday, November 14th. This represents a $2.08 annualized dividend and a yield of 2.49%. Eli Lilly and’s dividend payout ratio is currently 98.58%.

About Eli Lilly and

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with Analyst Ratings Network's FREE daily email newsletter.